Related Experiment Video
Updated: Aug 18, 2025

Real-time Imaging of Axonal Transport of Quantum Dot-labeled BDNF in Primary Neurons
Published on: September 15, 2014
Nrf2 Pathway in Huntington's Disease (HD): What Is Its Role?
Paolo Tucci1, Roberta Lattanzi2, Cinzia Severini3
1Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Abstract:
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease that occurs worldwide. Despite some progress in understanding the onset of HD, drugs that block or delay symptoms are still not available. In recent years, many treatments have been proposed; among them, nuclear transcriptional factor-2 (Nrf2) enhancer compounds have been proposed as potential therapeutic agents to treat HD. Nrf2 triggers an endogenous antioxidant pathway activated in different neurodegenerative disorders. Probably, the stimulation of Nrf2 during either the early phase or before HD symptoms' onset, could slow or prevent striatum degeneration. In this review, we present the scientific literature supporting the role of Nrf2 in HD and the potential prophylactic and therapeutic role of this compound.
More Related Videos
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Neural Regulation
MAPK Signaling Cascades
Regulation of the Unfolded Protein Response
Hedgehog Signaling Pathway
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

